phrykt

Bio-Rad Laboratories, Inc. (BIO): who owns it and who trades it

As of Nov 16, 2026, BIO insiders reported 4 open-market sales worth $1.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was James Barry (Vice president), with $540K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Bio-Rad Laboratories

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BIO

397 funds and institutions reported BIO shares worth $6.6B at the end of Q2 2026. The largest holder is First Eagle Investment Management, LLC with $1.5B.

10 largest owners, by value

First Eagle Investment Management, LLC$1.5B
BlackRock, Inc.$499M
Dimensional Fund Advisors LP$277M
Vanguard Capital Management LLC$243M
Ariel Investments, LLC$240M
Vanguard Portfolio Management LLC$240M
Earnest Partners LLC$171M
State Street Corp$168M
Bank of America Corp$144M
Assenagon Asset Management S.A.$137M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
First Eagle Investment Management, LLC5.21M–$1.5B+100%
BlackRock, Inc.1.70M–$499M+1%
Dimensional Fund Advisors LP944,548–$277M-13%
Vanguard Capital Management LLC826,972–$243M-1%
Ariel Investments, LLC816,751–$240M+4%
Vanguard Portfolio Management LLC816,198–$240M-2%
Earnest Partners LLC580,752–$171M-1%
State Street Corp571,762–$168M+2%
Bank of America Corp490,412–$144M+10%
Assenagon Asset Management S.A.466,454–$137M+216%
Capital World Investors462,457–$136M+3%
Capital Research Global Investors443,483–$130M+15%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC418,884–$123M-2%
First Pacific Advisors, LP401,861–$118M-1%
Geode Capital Management, LLC347,575–$102M-5%
Nomura Holdings Inc328,897–$96.6M+51%
UBS Group AG308,325–$90.5M-13%
Sei Investments Co273,377–$80.3M-5%
Barclays PLC267,634–$78.6M-4%
Deerfield Management Company, L.P.226,070–$66.4MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BIO insiders reported $0 of open-market purchases and $1.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.4M
4 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$1.2M$1.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Courtney C EnloeVice presidentSale902$386.17$348KForm 4
Nov 9, 2026James BarryVice presidentSale1,400$385.63$540KForm 4
Nov 9, 2026Jonathan P. DiVincenzoPresidentSale919$390.47$359KForm 4
May 11, 2026Eva Anette EngelhardtVice presidentSale550$246.54$136KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
James BarryEVP, President, LSG–$540KNov 9, 2026
Jonathan P. DiVincenzoPresident & COO–$359KNov 9, 2026
Courtney C EnloeEVP, General Counsel & Sec–$348KNov 10, 2026
Eva Anette EngelhardtEVP, President, CDG–$136KMay 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BIO short interest

1.16M BIO shares are sold short. Over the last 12 reports the number of shares short went down 14%.

As of Oct 30, 2026, 1.16M BIO shares were sold short, up 5.4% from the report before. At the average daily volume of 228,195 shares, buying them all back would take about 5.1 trading days (days to cover).

Shares short

1.16MMay 15Oct 301.64M

Days to cover

5.1May 15Oct 306.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.16M–+5%228,1955.1
Oct 15, 20261.10M–-7%226,5554.8
Sep 30, 20261.18M–+18%276,8874.3
Sep 15, 2026998,654–-12%260,9593.8
Aug 31, 20261.13M–-15%266,6094.2
Aug 14, 20261.33M–-6%275,2014.8
Jul 31, 20261.41M–-9%329,4354.3
Jul 15, 20261.56M–+3%261,5636.0
Jun 30, 20261.52M–-0%372,1364.1
Jun 15, 20261.52M–+1%347,4084.4
May 29, 20261.51M–+12%577,7892.6
May 15, 20261.34M–+23%459,3532.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Bio-Rad Laboratories company events

Bio-Rad Laboratories filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, job cuts). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  3. Apr 30, 2026ResultsReleased financial results. Filing
  4. Apr 24, 2026LeadershipAt the annual meeting of stockholders of Bio-Rad Laboratories, Inc., as further described in Item 5.07 below, the Company’s stockholders approved the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan. Filing
  5. Feb 19, 2026AnnouncementShared information with investors. Filing
  6. Feb 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Bio-Rad Laboratories financials

Famous investors that hold BIO

6 of the 50 well-known investors we track reported holding BIO in their latest 13F filing. The largest position is Ken Fisher's, worth $43.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026114,719$43.3M0.0%-2%
David Einhorn · Greenlight Capital (DME)Q3 2026103,990$39.3M1.1%New
Israel Englander · Millennium ManagementQ3 202695,395$36M0.0%+59%
Ken Griffin · Citadel AdvisorsQ3 202619,563$7.4M0.0%-68%
Paul Tudor Jones · Tudor Investment CorpQ3 20264,284$1.6M0.0%-83%
Ray Dalio · Bridgewater AssociatesQ3 2026749$283K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Bio-Rad Laboratories, Inc. (BIO) stock

Who owns the most BIO stock?

The largest reported owner of Bio-Rad Laboratories, Inc. (BIO) is First Eagle Investment Management, LLC. In total, 397 funds and institutions reported holding BIO at the end of Q2 2026. See the largest owners.

Are BIO insiders buying or selling?

In the last 12 months, BIO insiders reported no open-market purchases and 4 sales worth $1.4M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in BIO?

As of Oct 30, 2026, 1.16M BIO shares were sold short, up 5.4% from the report before. At the average daily volume of 228,195 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.

Which famous investors hold BIO?

6 of the 50 well-known investors we track reported BIO in their latest 13F filing, including Ken Fisher, David Einhorn, Israel Englander. The largest position is worth $43.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.